Transaction Information
Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced the closing of its previously announced underwritten public offering of 3,000,000 shares of its common stock at the public offering price of $75.00 per share. The aggregate gross proceeds to Axsome, before deducting underwriting discounts and commissions and offering expenses, were $225.0 million.
Axsome intends to use the proceeds from this offering to advance its late-stage pipeline, including funding existing and potential new clinical programs, products, and product candidates, to expand its commercialization efforts, and for other general corporate purposes.
Ladenburg Thalmann & Co. Inc. acted as one of the Lead Managers in connection with this offering.
About Axsome Therapeutics, Inc.
Axsome Therapeutics is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. For more information on Axsome visit https://www.axsome.com/.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.